PI3K抑制剂idelalisib和BTK抑制剂ibrutinib对复发的滤泡性淋巴瘤显示出很好的潜力。
The PI3K deltainhibitor idelalisib (Zydelig) and the BTK inhibitor ibrutinib (Imbruvica) have shown promise for patients with relapsed follicular lymphoma.
此外，一项二期研究将利妥昔单抗和pembrolizumab联合来治疗复发的滤泡性淋巴瘤。
Additionally, a phase II study is looking at the combination of rituximab and pembrolizumab (Keytruda) for patients with relapsed follicular lymphoma (NCT02446457).
二期的CheckMate- 140试验正在探索用nivolumab治疗经cd 20抗体和烷化剂治疗后进展的滤泡性淋巴瘤。
The phase II CheckMate-140 trial is exploring nivolumab (Opdivo) for patients with follicular lymphoma following progression on a CD20 antibody and an alkylating agent (NCT02038946).
2016年2月底，FDA批准了对接受过利妥昔单抗治疗的滤泡性淋巴瘤患者使用抗CD20单抗obinutuzumab和苯达莫司汀联合的方案。
In late February 2016, the FDA approved the anti-CD20 agent obinutuzumab(Gazyva) in combination with bendamustine for patients with follicular lymphoma following rituximab-based therapy.
2016年2月底，FDA批准了对接受过利妥昔单抗治疗的滤泡性淋巴瘤患者使用抗CD20单抗obinutuzumab和苯达莫司汀联合的方案。
In late February 2016, the FDA approved the anti-CD20 agent obinutuzumab(Gazyva) in combination with bendamustine for patients with follicular lymphoma following rituximab-based therapy.
应用推荐